Insilico Medicine Reaches $600M AI Drug Discovery Partnership With Takeda

According to Insilico Medicine, the company reached a strategic collaboration with Takeda Pharmaceutical today worth up to $600 million to advance AI-driven drug discovery. Insilico will leverage its Pharma.AI platform to identify drug candidates in disease areas selected by Takeda, while Takeda will handle clinical development and commercialization globally.

Under the agreement, Insilico receives $60 million in upfront payments and near-term milestone fees, with potential total consideration reaching $600 million including development milestones and tiered royalties on future sales.

Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments